Cargando…

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes

OBJECTS: Imigliptin is a novel dipeptidyl peptidase-4 inhibitor. In the present study, we aimed to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function in Chinese patients with type-2 diabetes mellitus (T2DM). METHODS: A total of 37 Chinese T2DM patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xu, Liu, Yang, Liu, Hongzhong, Li, Haiyan, Yang, Jianhong, Hu, Pei, Xiao, Xinhua, Liu, Dongyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488395/ https://www.ncbi.nlm.nih.gov/pubmed/34616361 http://dx.doi.org/10.3389/fendo.2021.694390

Ejemplares similares

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits
por: Zhang, Xiaowei, et al.
Publicado: (2017)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
por: Cao, Fen, et al.
Publicado: (2021)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
por: Zhao, Dandan, et al.
Publicado: (2018)

The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
por: Yang, Qiu, et al.
Publicado: (2022)

Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
por: Kurozumi, Akira, et al.
Publicado: (2013)

In Silico Approaches Applied to the Study of Peptide Analogs of Ile-Pro-Ile in Relation to Their Dipeptidyl Peptidase IV Inhibitory Properties
por: Nongonierma, Alice B., et al.
Publicado: (2018)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study
por: Takamiya, Yosuke, et al.
Publicado: (2020)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
por: Nojima, Hiroyuki, et al.
Publicado: (2016)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
por: Chai, Shangyu, et al.
Publicado: (2022)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

In-Vitro Studies on Selected Jordanian Plants as Dipeptidyl Peptidase-IV Inhibitors for Management of Diabetes Mellitus
por: Sewidan, Nuha, et al.
Publicado: (2020)

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice
por: Akita, Koji, et al.
Publicado: (2015)

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2022)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2023)

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
por: Joo, Kwon Wook, et al.
Publicado: (2013)

Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor
por: Rozano, Lina, et al.
Publicado: (2017)

Identification and Characterization of Dipeptidyl Peptidase-IV Inhibitory Peptides from Oat Proteins
por: Wang, Wei, et al.
Publicado: (2022)

Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review
por: Liu, Rui, et al.
Publicado: (2019)

Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes
por: Wang, Zhongsu, et al.
Publicado: (2021)

Dipeptidyl Peptidase IV Inhibitor MK-0626 Attenuates Pancreatic Islet Injury in Tacrolimus-Induced Diabetic Rats
por: Jin, Long, et al.
Publicado: (2014)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2020)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
por: Yang, Yinqiu, et al.
Publicado: (2017)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
por: Michel, Martin C., et al.
Publicado: (2008)

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
por: Mohammad, Badrud Duza, et al.
Publicado: (2022)

The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes
por: Jao, Chia-Ling, et al.
Publicado: (2015)

Dipeptidyl Peptidase IV and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) study
por: Luft, Vivian C., et al.
Publicado: (2010)

Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease
por: Zhang, Yuanyuan, et al.
Publicado: (2022)

Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure
por: Salles, Thiago A., et al.
Publicado: (2015)

Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis
por: Larrinaga, Gorka, et al.
Publicado: (2015)

Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
por: Batel-Marques, Francisco, et al.
Publicado: (2019)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lbo6tkjdjj1geuc8c27dd3hp7c